JP2025509988A - Ｍｇｌｕｒ５調節化合物、組成物、及び使用方法 - Google Patents

Ｍｇｌｕｒ５調節化合物、組成物、及び使用方法 Download PDF

Info

Publication number
JP2025509988A
JP2025509988A JP2024556189A JP2024556189A JP2025509988A JP 2025509988 A JP2025509988 A JP 2025509988A JP 2024556189 A JP2024556189 A JP 2024556189A JP 2024556189 A JP2024556189 A JP 2024556189A JP 2025509988 A JP2025509988 A JP 2025509988A
Authority
JP
Japan
Prior art keywords
compound
degrees
solvate
solvate form
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509988A5 (https=
Inventor
ジーガート，ティモシー，ライアン
ストリットマター，スティーブン
スカラヴェッリ，フェデリコ
コラ，カミッラ
Original Assignee
アリックス セラピューティクス インコーポレイテッド
イェール大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリックス セラピューティクス インコーポレイテッド, イェール大学 filed Critical アリックス セラピューティクス インコーポレイテッド
Publication of JP2025509988A publication Critical patent/JP2025509988A/ja
Publication of JP2025509988A5 publication Critical patent/JP2025509988A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024556189A 2022-03-22 2023-03-22 Ｍｇｌｕｒ５調節化合物、組成物、及び使用方法 Pending JP2025509988A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263322446P 2022-03-22 2022-03-22
US63/322,446 2022-03-22
PCT/US2023/015966 WO2023183428A1 (en) 2022-03-22 2023-03-22 Mglur5 modulating compounds, compositions, and methods of use

Publications (2)

Publication Number Publication Date
JP2025509988A true JP2025509988A (ja) 2025-04-11
JP2025509988A5 JP2025509988A5 (https=) 2026-03-31

Family

ID=88101942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556189A Pending JP2025509988A (ja) 2022-03-22 2023-03-22 Ｍｇｌｕｒ５調節化合物、組成物、及び使用方法

Country Status (9)

Country Link
US (1) US20250230149A1 (https=)
EP (1) EP4496572A4 (https=)
JP (1) JP2025509988A (https=)
KR (1) KR20250008042A (https=)
CN (1) CN119300827A (https=)
AU (1) AU2023238896A1 (https=)
CA (1) CA3246263A1 (https=)
IL (1) IL315809A (https=)
WO (1) WO2023183428A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080252A1 (en) * 2023-10-13 2025-04-17 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2025188734A1 (en) * 2024-03-06 2025-09-12 Allyx Therapeutics, Inc. Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691821B2 (en) * 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5

Also Published As

Publication number Publication date
WO2023183428A8 (en) 2023-12-14
AU2023238896A1 (en) 2024-10-03
KR20250008042A (ko) 2025-01-14
CA3246263A1 (en) 2023-09-28
EP4496572A1 (en) 2025-01-29
US20250230149A1 (en) 2025-07-17
CN119300827A (zh) 2025-01-10
EP4496572A4 (en) 2026-03-11
WO2023183428A1 (en) 2023-09-28
IL315809A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP6948426B2 (ja) 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
TWI808108B (zh) N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
EA022924B1 (ru) ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
JP2025509988A (ja) Ｍｇｌｕｒ５調節化合物、組成物、及び使用方法
TW201720438A (zh) 用於治療醫學病症之化合物
TW201444834A (zh) 選擇性ｃｄｋ４／６抑制劑之固態形式
KR20110071064A (ko) (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
JP2021536511A (ja) ダニコパンの形態
WO2004022538A1 (ja) 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬
JP2020172526A (ja) 結晶性抗体製剤
IL268092B2 (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
KR20260026542A (ko) 포시펜 d-타르트레이트의 고체 형태
WO2024024961A1 (ja) ２（１ｈ）－ピリジンイミン誘導体
CN113330007A (zh) 尼拉帕利游离碱的晶体形式
WO2025157131A1 (zh) 大环类衍生物的晶型及其制备方法和用途
JP2005511639A (ja) 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体
WO2025080252A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
AU2023468841A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
WO2025188734A1 (en) Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one
KR102399374B1 (ko) 알츠하이머병의 치료를 위한 ｎ-[2-(6-플루오로-1ｈ-인돌-3-일)에틸]-3-(2,2,3,3-테트라플루오로프로폭시)벤질아민 히드로클로라이드의 신규한 다형체 형태
TW202547500A (zh) 用於抑制ｗｅｒｎｅｒ氏症候群ａｔｐ依賴性解旋酶之化合物及方法
KR102065236B1 (ko) 속방형 덱사메타손 및 서방형 온단세트론을 포함하는 1일 1회 복합 구강 속붕해정 및 이의 제조방법
US11306080B2 (en) Crystalline form of a BACE inhibitor, compositions, and use
US20220289587A1 (en) A novel polymorph and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260323